No Section 40A(2)(a) addition if AO not brought any comparable case to demonstrate that payments made by assessee to directors were excessive/unreasonable: ...

HealthDay News — The US Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as replies to drug and biological product applications submitted ...